| pubmed-article:15605123 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C0004609 | lld:lifeskim |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C0013470 | lld:lifeskim |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C0095175 | lld:lifeskim |
| pubmed-article:15605123 | lifeskim:mentions | umls-concept:C0615055 | lld:lifeskim |
| pubmed-article:15605123 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15605123 | pubmed:dateCreated | 2004-12-17 | lld:pubmed |
| pubmed-article:15605123 | pubmed:abstractText | It has previously been demonstrated that central administration of the GABAB agonist baclofen increases food intake in non-deprived or satiated animals by action at the central GABAB receptors. It has also been shown that systemic administration of baclofen increases food intake in non-deprived rats. Although baclofen crosses the blood brain barrier from systemic circulation to enter the brain, it is conceivable that it may increase food intake by a peripheral mode of action. This possibility was examined in the present study. The effects of intraperitoneal (i.p.) administration of the GABAB receptor agonists baclofen and 3-aminopropylphosphinic acid (3-APA) were investigated on food intake in non-deprived rats. 3-APA is a potent GABAB agonist that does not penetrate the blood brain barrier. The results show that while baclofen (1-4 mg/kg) increases food intake in a dose-related manner, 3-APA (0.5-2 mg/kg) has no effects on food consumption. The results indicate that a peripheral GABAB mechanism is not involved in the hyperphagia elicited by systemic administration of baclofen and suggests that the drug increases food intake by a central mode of action. | lld:pubmed |
| pubmed-article:15605123 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15605123 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15605123 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15605123 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15605123 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15605123 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15605123 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15605123 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15605123 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15605123 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15605123 | pubmed:issn | 0379-0355 | lld:pubmed |
| pubmed-article:15605123 | pubmed:author | pubmed-author:PatelS MSM | lld:pubmed |
| pubmed-article:15605123 | pubmed:author | pubmed-author:EbenezerI SIS | lld:pubmed |
| pubmed-article:15605123 | pubmed:copyrightInfo | (c) 2004 Prous Science | lld:pubmed |
| pubmed-article:15605123 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15605123 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:15605123 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15605123 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15605123 | pubmed:pagination | 627-30 | lld:pubmed |
| pubmed-article:15605123 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:meshHeading | pubmed-meshheading:15605123... | lld:pubmed |
| pubmed-article:15605123 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15605123 | pubmed:articleTitle | Effects of the GABAB receptor agonists baclofen and 3-aminopropylphosphinic acid (3-APA) on food intake in rats. | lld:pubmed |
| pubmed-article:15605123 | pubmed:affiliation | Neuropharmacology Research Group, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, England. ivor.ebenezer@port.ac.uk | lld:pubmed |
| pubmed-article:15605123 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15605123 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15605123 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15605123 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15605123 | lld:pubmed |
